Alpha 2.0
Login Register
» Articles » PMID: 14976063

Prophylaxis with Defibrotide Prevents Veno-occlusive Disease in Stem Cell Transplantation After Gemtuzumab Ozogamicin Exposure

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2004 Feb 21
PMID 14976063
Citations 8
Authors
Brigitta Versluys
Rajat Bhattacharaya
Colin Steward
Jackie Cornish
Anthony Oakhill
Nick Goulden
Affiliations
Soon will be listed here.
Citing Articles

Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies.

Ma H, Sawas A Curr Hematol Malig Rep. 2018; 13(6):555-569.

PMID: 30362019 DOI: 10.1007/s11899-018-0485-3.

Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation.

Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle J Bone Marrow Transplant. 2017; 53(2):138-145.

PMID: 28759025 PMC: 5803572. DOI: 10.1038/bmt.2017.161.

Sinusoidal obstructive syndrome prophylaxis with recombinant human soluble thrombomodulin is feasible in gemtuzumab ozogamicin-treated patients undergoing allogeneic hematopoietic cell transplantation.

Yamamoto S, Matsuno R, Sugishita Y, Kaneko R, Okamoto N, Koganesawa M Bone Marrow Transplant. 2017; 52(7):1068-1070.

PMID: 28368378 DOI: 10.1038/bmt.2017.65.

Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: Prophylaxis and treatment controversies.

Cheuk D World J Transplant. 2013; 2(2):27-34.

PMID: 24175193 PMC: 3782230. DOI: 10.5500/wjt.v2.i2.27.

Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin.

Cowan A, Laszlo G, Estey E, Walter R Front Biosci (Landmark Ed). 2013; 18(4):1311-34.

PMID: 23747885 PMC: 3683663. DOI: 10.2741/4181.